CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $116.6M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 5.91: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
165.17BKRW116.60M · vs all stocks (USD)
Trailing P/E
34.93xvs Biotechnology peers
Revenue (TTM)
32.34BKRW22.83M · vs all stocks (USD)
Profit Margin
22.56%vs Biotechnology peers
Beta
0.5380xvs all stocks
52-Week Change
-41.53%vs all stocks
Market Capitalization
165.17BKRW116.60M · vs all stocks (USD)
Enterprise Value
155.34BKRW109.66M · vs all stocks (USD)
Trailing P/E
34.93xvs Biotechnology peers
PEG Ratio
-0.2017xvs Biotechnology peers
Price to Sales (TTM)
5.34xvs Biotechnology peers
Price to Book (MRQ)
3.51xvs Biotechnology peers
Enterprise to Revenue
4.80xvs Biotechnology peers
Enterprise to EBITDA
15.99xvs Biotechnology peers
Gross Margin
57.01%vs Biotechnology peers
Profit Margin
22.56%vs Biotechnology peers
Operating Margin
2.62%vs Biotechnology peers
Return on Assets (TTM)
6.58%vs Biotechnology peers
Return on Equity (TTM)
18.77%vs Biotechnology peers
Revenue (TTM)
32.34BKRW22.83M · vs all stocks (USD)
Revenue per Share (TTM)
2.93KKRWUpdated Jul 14, 2026Quarterly Revenue Growth
-6.70%vs Biotechnology peers
Gross Profit (TTM)
20.59BKRW14.53M · vs all stocks (USD)
EBITDA (TTM)
8.78BKRW6.20M · vs all stocks (USD)
Net Income (TTM)
7.30BKRW5.15M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-6.69%vs Biotechnology peers
Operating Cash Flow (TTM)
9.43BKRW6.66M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-3.18BKRW-2.25M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
32.72BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
11.94BKRWFY2025 · Dec 31, 2025Gross Profit
20.78BKRWFY2025 · Dec 31, 2025Operating Income
5.03BKRW3.55M · vs all stocks (USD)
Pre-tax Income
4.61BKRWFY2025 · Dec 31, 2025Income Tax Expense
-28.67MKRWFY2025 · Dec 31, 2025Net Income
4.64BKRWFY2025 · Dec 31, 2025EBIT
5.12BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
8.78BKRWFY2025 · Dec 31, 2025Research & Development
5.61BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
6.12BKRWFY2025 · Dec 31, 2025Other Operating Expenses
67.82MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
360.34MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
506.19MKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
4.64BKRWFY2025 · Dec 31, 2025Operating Cash Flow
1.31BKRWFY2025 · Dec 31, 2025Free Cash Flow
-172.06MKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
22.05BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
4.64BKRWFY2025 · Dec 31, 2025Other Non-cash Items
125.09MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
476.30MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.93BKRWFY2025 · Dec 31, 2025Capital Expenditures
-1.48BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-3.79BKRWFY2025 · Dec 31, 2025Purchase of Investments
-100.00MKRWFY2025 · Dec 31, 2025Sale of Investments
830.00MKRWFY2025 · Dec 31, 2025Other Investing Activity
-33.51MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-785.10MKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-2.42BKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-640.22MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-2.95BKRWFY2025 · Dec 31, 2025Shares Outstanding
11.37MSharesUpdated Jul 14, 2026Float Shares
9.02MSharesUpdated Jul 14, 2026% Held by Insiders
19.28%vs all stocks
% Held by Institutions
1.97%vs all stocks
Total Cash (MRQ)
24.18BKRW17.07M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.16KKRWUpdated Jul 14, 2026Total Debt (MRQ)
9.71BKRW6.85M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2065xvs Biotechnology peers
Current Ratio (MRQ)
3.35xvs Biotechnology peers
Book Value per Share (MRQ)
4.13KKRWUpdated Jul 14, 2026Total Assets
63.00BKRW44.47M · vs all stocks (USD)
Total Current Assets
37.37BKRWFY2025 · Dec 31, 2025Total Liabilities
17.18BKRWFY2025 · Dec 31, 2025Total Non-current Assets
25.63BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
5.36BKRWFY2025 · Dec 31, 2025Total Current Liabilities
11.82BKRWFY2025 · Dec 31, 2025Cash Equivalents
22.05BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
22.05BKRWFY2025 · Dec 31, 2025Other Short-term Investments
1.29BKRWFY2025 · Dec 31, 2025Accounts Receivable
7.37BKRWFY2025 · Dec 31, 2025Inventory
5.45BKRWFY2025 · Dec 31, 2025Accounts Payable
323.22MKRWFY2025 · Dec 31, 2025Short-term Debt
8.61BKRWFY2025 · Dec 31, 2025Other Current Liabilities
-630.00KRWFY2025 · Dec 31, 2025Long-term Debt
1.40BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
10.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
5.68BKRWFY2025 · Dec 31, 2025Retained Earnings
-50.99BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
45.82BKRW32.35M · vs all stocks (USD)
52-Week Low
14.25KKRWUpdated Jul 14, 202652-Week High
54.30KKRWUpdated Jul 14, 202652-Week Change
-41.53%vs all stocks
Beta
0.5380xvs all stocks
50-Day MA
20.09KKRWUpdated Jul 14, 2026200-Day MA
31.24KKRWUpdated Jul 14, 2026Avg 10-Day Volume
24.52KSharesUpdated Jul 14, 2026Avg 30-Day Volume
36.11KSharesUpdated Jul 14, 2026Diluted EPS (TTM)
413.00KRWUpdated Jul 14, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.91: safe zoneNotable
Altman Z-Score: 5.91
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $116.6M, lower than 95% of all stocks globallySignificant
Market cap (USD): 116,596,349.394Global P5: 269,387,740.27
Revenue is $22.83M, lower than 95% of all stocks globallySignificant
Revenue (USD): 22,831,115.298Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Polaryx Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Engene Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
Faron Pharmaceuticals Oy
Tier 1ProductionApproval-Gated PipelineRuleRisk
Y-Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cellbion Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
PepGen Inc.
Tier 1ProductionApproval-Gated PipelineRule
3Billion Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
CVRx, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pyridam Farma Tbk.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bonus BioGroup Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Village Farms International Inc.
2 interpretationsMinimal Tax and Interest DragMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Çelebi Hava Servisi A.Ş.
2 interpretationsMinimal Tax and Interest DragIndustry-Benchmarked Return on Capital Elevated
Jahwa Electronics Co., Ltd.
2 interpretationsMinimal Tax and Interest DragIndustry-Benchmarked Return on Capital Elevated